/BHVN

BHVN Stock - Biohaven Ltd.

Q: What is the analyst price target for BHVN?

Analyst price target information is not currently available for BHVN.

Q: What is BHVN's market cap?

Market capitalization information is not currently available for BHVN.

Healthcare|Biotechnology|NYSE

$10.97-7.35%

$0.87 (-7.35%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+105.1%upside

Target: $22.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BHVN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.54

52W High$44.28

52W Low$7.48

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-885,111,000	$-436,051,000	$-567,932,000	$-218,900,000	$-114,506,000
Net Income	$-846,422,000	$-408,168,000	$-570,279,000	$-213,796,000	$-118,668,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-9.28	$-5.73	$-12.75	$-5.97	$-3.31

Company Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Visit Website

Earnings History & Surprises

BHVN

Beat Rate

16%

Last 19 quarters

Avg Surprise

-31.9%

EPS vs Estimate

Beats / Misses

3/14

2 met exactly

Latest EPS

$-1.64

Q4 2025

EPS Surprise History

Q1 24

-28.4%

$-1.81vs$-1.41

Q2 24

-46.7%

$-2.20vs$-1.50

Q3 24

-111.6%

$-3.64vs$-1.72

Q4 24

0.0%

$-1.70vs$-1.70

Q1 25

-18.6%

$-1.85vs$-1.56

Q2 25

-29.9%

$-2.17vs$-1.67

Q3 25

0.0%

$-1.94vs$-1.94

Q4 25

+14.1%

$-1.64vs$-1.91

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 2, 2026	$-1.23	—	—	—
Q4 2025	Nov 10, 2025	$-1.91	$-1.64	+14.1%	✓ BEAT
Q3 2025	Aug 11, 2025	$-1.94	$-1.94	0.0%	= MET
Q2 2025	May 12, 2025	$-1.67	$-2.17	-29.9%	✗ MISS
Q1 2025	Mar 3, 2025	$-1.56	$-1.85	-18.6%	✗ MISS
Q4 2024	Nov 12, 2024	$-1.70	$-1.70	0.0%	= MET
Q3 2024	Aug 8, 2024	$-1.72	$-3.64	-111.6%	✗ MISS
Q2 2024	May 9, 2024	$-1.50	$-2.20	-46.7%	✗ MISS
Q1 2024	Feb 29, 2024	$-1.41	$-1.81	-28.4%	✗ MISS
Q4 2023	Nov 14, 2023	$-1.33	$-1.50	-12.8%	✗ MISS
Q3 2023	Jul 31, 2023	$-1.24	$-1.32	-6.5%	✗ MISS
Q2 2023	May 12, 2023	$-1.39	$-1.03	+25.9%	✓ BEAT
Q1 2023	Mar 23, 2023	$-1.24	$-3.32	-167.7%	✗ MISS
Q4 2022	Nov 9, 2022	$-2.53	$-1.75	+30.8%	✓ BEAT
Q3 2022	Aug 5, 2022	$-2.79	$-6.21	-122.6%	✗ MISS
Q2 2022	May 10, 2022	$-2.52	$-2.97	-17.9%	✗ MISS
Q1 2022	Feb 25, 2022	$-2.07	$-3.01	-45.4%	✗ MISS
Q4 2021	Nov 9, 2021	$-2.44	$-2.63	-7.8%	✗ MISS
Q3 2021	Aug 9, 2021	$-2.77	$-3.23	-16.6%	✗ MISS
Q2 2021	May 10, 2021	$-2.92	$-4.21	-44.2%	✗ MISS